Navigation Links
Common alternative treatment for liver disease is found to be ineffective

Results of high-quality randomized clinical trials have determined that milk thistle extract, a widely used alternative medication, may not have any significant influence on the course of patients with alcoholic liver disease or hepatitis B or C liver disease. These findings are published in The American Journal of Gastroenterology.

According to the previous studies, milk thistle extracts have been shown to possess properties that protect against various hepatotoxins, including the prevention of lipid perioxidation, which is frequent in all stages of liver damage in alcoholic and non-alcoholic liver disease.

"The ironic fact is," notes Christian Gluud of the Copenhagen Trial Unit, Center for Clinical Intervention Research at the Copenhagen University Hospital, "that even though milk thistle and milk thistle extracts have been widely examined, we are still not in a situation where we can exclude a potential beneficial or harmful effect."

In this study, researchers aimed to determine the exact benefits or harm in using milk thistle to treat affected patients. Over 900 patients with the aforementioned types of liver disease were studied in these trials over a period of six months, in groups treated with milk thistle versus placebo treatment. No significant effects were observed on mortality or complication of the disease. Further, milk thistle was not associated with any significant risk of adverse events.

"It would be logical to stop the use of milk thistle products, not to reimburse any use, to stop the information that milk thistle products may be used, and to support further trials," adds Gluud.


'"/>

Source:Blackwell Publishing Ltd.


Page: 1

Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common molecular signature identified in solid tumors
7. Common bacteria pirate natural mechanism to get inside cells
8. Commonly used antidepressants may also affect human immune system
9. Common practices at petting zoos put visitors at risk
10. Common enzyme is a key player in DNA repair
11. Common molecular signature identified in solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):
(Date:4/19/2017)... ... April 19, 2017 , ... ... financing round. This event adds to several other early achievements at ThermaGenix, including ... Scientific Teams. , ThermaGenix will use proceeds from the Series A-1 ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of the ... to novices as well as experienced users, attendees will gain a better understanding ... tests. , Hemostasis testing quality is determined by preanalytical variables which encompass ...
(Date:4/19/2017)... , April 19, 2017  As a ... Abuse and Heroin Summit ,  Proove┬« Biosciences, Inc. ... analyzing genetics, environmental, and lifestyle factors to accurately ... the University of Southern California (USC), the Interventional ... and Proove publish results showing that Proove Opioid ...
(Date:4/19/2017)... , April 19, 2017 ... today announced that it will report its first ... on Wednesday, May 3, 2017. Following the announcement, Veracyte,s management will ... p.m. Eastern Time to discuss the company,s financial results ... and subsequent replay may be accessed by visiting Veracyte,s website ...
Breaking Biology Technology: